This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
For patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin (UFH) being administered by continuous infusion, stop the infusion and start XARELTO at the same time.1
For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken.1
No clinical data is available to guide converting patients from apixaban to XARELTO, or from XARELTO to apixaban.
Clinicians should use their clinical judgement to weigh benefits vs risks for each patient and refer to product labeling for each product as appropriate.2-5
Additional citations are included in the REFERENCES section for your review.2-9
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 06 July 2026.
Raval AN, Cigarroa JE, Chung MK, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135(10):e604-e633.
Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 41(1):206-232.
Romagnoli A, Santoleri F, Costantini A, et al. Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years. Eur J Hosp Pharm. 2024;31(2):156-161.
Endchat
Chat live
Would you like to clear and leave your conversation? Message history will be lost.
Live video
Waiting for agent...
A Medical Information Specialist will assist you shortly. When your Specialist has joined, a button to join the video call will appear here.
Ready to join
Click or tap the button below to join the video call with your Medical Information Specialist: